Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.
Vittorio PengoAriela HoxhaLaura AndreoliAngela TincaniElena SilvestriDomenico PriscoTiziana FierroPaolo GreseleArturo CafollaValeria De MicheliAngelo GhirarduzziAlberto TosettoAnna FalangaIda MartinelliSophie TestaDoris BarcellonaMaria GerosaGentian DenasPublished in: Journal of thrombosis and haemostasis : JTH (2020)
These data further support the use of warfarin in high-risk patients with antiphospholipid syndrome.